Zhihui Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhihui Xu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Huasheng Yang
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China
3 shared publications - Huijing Ye
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China
3 shared publications - Anqi Sun
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Sun Yat-Sen University, Guangzhou 510060, China
2 shared publications - Te Zhang
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China
2 shared publications - Wei Xiao
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Sun Yat-Sen University, Guangzhou 510060, China
2 shared publications - Xiaotong Sha
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China
2 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Ophthalmology
- Vol. 2025 (1)
New Clues to the Pathogenesis of Idiopathic Orbital Inflammation: Elevated IL‐8 and MCP‐1 in Tear Fluid
Objectives: To characterize tear cytokine profiles in patients with idiopathic orbital inflammation (IOI) and analyze the expression of altered cytokines in blood and involved tissues. Methods: This case‐control study enrolled 18 IOI patients and 11 age‐/sex‐matched controls. Ocular Surface Disease Index (OSDI), corneal fluorescent staining, tear film breakup time (TBUT), Schirmer I test, and other clinical and laboratory parameters were obtained from all participants. Concentrations of cytokines in tear fluid, blood, and tissues were determined using a multiplex bead immunoassay system, enzyme‐linked immunosorbent assay, and immunohistochemistry. Results: Significantly elevated levels of interleukin (IL)‐8 and monocyte chemoattractant protein (MCP)‐1 (both p < 0.05) were found in IOI tear fluid. The area under receiver operating characteristic curve was 0.73 and 0.74 for IL‐8 and MCP‐1, respectively. IL‐8 and MCP‐1 were overexpressed in orbital tissues from patients with IOI, while the plasma levels of IL‐8 and MCP‐1 in the IOI group were parallel to the control group. Conclusions: The dysregulation of tear cytokine profiles provides a new insight into the potential immunologic mechanism for IOI. The elevated IL‐8 and MCP‐1 may represent candidate biomarkers of IOI.
- 1 January 2025
- Published by Wiley in Journal of Ophthalmology
- Vol. 2025 (1)
Open AccessNew Clues to the Pathogenesis of Idiopathic Orbital Inflammation: Elevated IL‐8 and MCP‐1 in Tear Fluid
Objectives: To characterize tear cytokine profiles in patients with idiopathic orbital inflammation (IOI) and analyze the expression of altered cytokines in blood and involved tissues. Methods: This case‐control study enrolled 18 IOI patients and 11 age‐/sex‐matched controls. Ocular Surface Disease Index (OSDI), corneal fluorescent staining, tear film breakup time (TBUT), Schirmer I test, and other clinical and laboratory parameters were obtained from all participants. Concentrations of cytokines in tear fluid, blood, and tissues were determined using a multiplex bead immunoassay system, enzyme‐linked immunosorbent assay, and immunohistochemistry. Results: Significantly elevated levels of interleukin (IL)‐8 and monocyte chemoattractant protein (MCP)‐1 (both p < 0.05) were found in IOI tear fluid. The area under receiver operating characteristic curve was 0.73 and 0.74 for IL‐8 and MCP‐1, respectively. IL‐8 and MCP‐1 were overexpressed in orbital tissues from patients with IOI, while the plasma levels of IL‐8 and MCP‐1 in the IOI group were parallel to the control group. Conclusions: The dysregulation of tear cytokine profiles provides a new insight into the potential immunologic mechanism for IOI. The elevated IL‐8 and MCP‐1 may represent candidate biomarkers of IOI.
- Open Access
- 6 May 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (9) , 8356
Serelaxin Alleviates Fibrosis in Thyroid-Associated Ophthalmopathy via the Notch Pathway
Fibrosis is the late stage of thyroid-associated ophthalmopathy (TAO), resulting in serious complications. Effective therapeutic drugs are still lacking. We aimed to explore the mechanism of TAO fibrosis and to find a targeted drug. High-throughput RNA sequencing was performed on orbital connective tissues from twelve patients with TAO and six healthy controls. Protein–protein interaction (PPI) network was constructed using the Search Tool for the Retrieval of Interacting Genes (STRING) database and we identified the hub gene by Cytoscape software. Additionally, the RNA sequencing results were validated by quantitative real-time polymerase chain reaction (qRT–PCR). Bioinformatic prediction identified the functions of differentially expressed genes (DEGs). Further orbital connective tissue and serum samples of the TAO and control groups were collected for subsequent experiments. Histologic staining, Western blotting (WB), qRT–PCR, enzyme-linked immunosorbent assays (ELISAs), gene overexpression through lentiviral infection or silencing gene by short interfering RNA (siRNA) were performed. We found that the relaxin signaling pathway is an important regulatory pathway in TAO fibrosis pathogenesis. Serelaxin exerts antifibrotic and anti-inflammatory effects in TAO. Furthermore, the downstream Notch pathway was activated by serelaxin and was essential to the antifibrotic effect of serelaxin in TAO. The antifibrotic effect of serelaxin is dependent on RXFP1.
- 6 May 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (9) , 8356
Open AccessSerelaxin Alleviates Fibrosis in Thyroid-Associated Ophthalmopathy via the Notch Pathway
Fibrosis is the late stage of thyroid-associated ophthalmopathy (TAO), resulting in serious complications. Effective therapeutic drugs are still lacking. We aimed to explore the mechanism of TAO fibrosis and to find a targeted drug. High-throughput RNA sequencing was performed on orbital connective tissues from twelve patients with TAO and six healthy controls. Protein–protein interaction (PPI) network was constructed using the Search Tool for the Retrieval of Interacting Genes (STRING) database and we identified the hub gene by Cytoscape software. Additionally, the RNA sequencing results were validated by quantitative real-time polymerase chain reaction (qRT–PCR). Bioinformatic prediction identified the functions of differentially expressed genes (DEGs). Further orbital connective tissue and serum samples of the TAO and control groups were collected for subsequent experiments. Histologic staining, Western blotting (WB), qRT–PCR, enzyme-linked immunosorbent assays (ELISAs), gene overexpression through lentiviral infection or silencing gene by short interfering RNA (siRNA) were performed. We found that the relaxin signaling pathway is an important regulatory pathway in TAO fibrosis pathogenesis. Serelaxin exerts antifibrotic and anti-inflammatory effects in TAO. Furthermore, the downstream Notch pathway was activated by serelaxin and was essential to the antifibrotic effect of serelaxin in TAO. The antifibrotic effect of serelaxin is dependent on RXFP1.
- Open Access
- 7 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (24) , 15508
Metformin Attenuates Inflammation and Fibrosis in Thyroid-Associated Ophthalmopathy
The pathogenesis of thyroid-associated ophthalmopathy (TAO) is still unclear, and therapeutic drugs have great limitations. As metformin has multiple therapeutic effects in many autoimmune diseases, we explored the effects of metformin on TAO in an in vitro fibroblast model. We used orbital connective tissues and fibroblasts that were obtained from TAO patients and normal controls. The activity of adenosine monophosphate-activated protein kinase (AMPK) and the levels of inflammatory or fibrotic factors were examined by immunofluorescence (IF) and immunohistochemistry (IHC). Quantitative real-time polymerase chain reaction (qPCR), cytokine quantification by enzyme-linked immunosorbent sssay (ELISA), IF, and western blotting (WB) were used to measure the expression of factors related to inflammation, fibrosis, and autophagy. To determine the anti-inflammatory and antifibrotic mechanisms of metformin, we pretreated cells with metformin, 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside (AICAR, an AMPK activator) or compound C (CC, an AMPK inhibitor) for 24 h and used WB to verify the changes in protein levels in the AMPK/mammalian target of rapamycin (mTOR) pathway. We determined that the low activity of AMPK in the periorbital tissue of TAO patients may be closely related to the occurrence and development of inflammation and fibrosis, and metformin exerts multiple effects by activating AMPK in TAO. Furthermore, we suggest that AMPK may be a potential target of TAO therapy.
- 7 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (24) , 15508
Open AccessMetformin Attenuates Inflammation and Fibrosis in Thyroid-Associated Ophthalmopathy
The pathogenesis of thyroid-associated ophthalmopathy (TAO) is still unclear, and therapeutic drugs have great limitations. As metformin has multiple therapeutic effects in many autoimmune diseases, we explored the effects of metformin on TAO in an in vitro fibroblast model. We used orbital connective tissues and fibroblasts that were obtained from TAO patients and normal controls. The activity of adenosine monophosphate-activated protein kinase (AMPK) and the levels of inflammatory or fibrotic factors were examined by immunofluorescence (IF) and immunohistochemistry (IHC). Quantitative real-time polymerase chain reaction (qPCR), cytokine quantification by enzyme-linked immunosorbent sssay (ELISA), IF, and western blotting (WB) were used to measure the expression of factors related to inflammation, fibrosis, and autophagy. To determine the anti-inflammatory and antifibrotic mechanisms of metformin, we pretreated cells with metformin, 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside (AICAR, an AMPK activator) or compound C (CC, an AMPK inhibitor) for 24 h and used WB to verify the changes in protein levels in the AMPK/mammalian target of rapamycin (mTOR) pathway. We determined that the low activity of AMPK in the periorbital tissue of TAO patients may be closely related to the occurrence and development of inflammation and fibrosis, and metformin exerts multiple effects by activating AMPK in TAO. Furthermore, we suggest that AMPK may be a potential target of TAO therapy.